Seer (SEER): Debts to Book Capitalization

The Seer, Inc. (SEER) price chart demonstrates the dynamics of an asset whose indicators stand at 0.10. Seer, Inc. (SEER) generates revenue through the sale of systems and ancillary materials for detailed protein study. The Proteograph method provides a technological advantage, enabling the rapid recognition of thousands of markers within a sample. Demand for these solutions is growing among pharmaceutical centers and research institutes.

SEER Seer, Inc. Debt to Book Value Ratio (07/04/2022 - 10/27/2026)

Summary analytical data breakdowns for Seer Inc (SEER)

- price and consensus price forecast:

Stock Price Seer, Inc.|SEER - Analyst Consensus Forecast

- market capitalization data:

Market Capitalization Seer Bio|SEER - Full Takeover Company Value

- book capitalization data:

Net Assets per Single Share Seer|SEER - Accounting Capitalization|Market Value to Book Value Ratio seer.bio|SEER - Company Assets

- debt and liquidity data:

Debt to Equity Seer, Inc.|SEER - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Equity Ratio Seer Inc.|SEER - Company Cumulative Indebtedness|Debts to Book Capitalization Seer Bio

Fundamental company analysis:Seer, Inc.

Integrating ESG standards into the production of proteomic equipment at Seer, Inc. (SEER) requires a precise balance between environmental investments and financial sustainability. This capital structure risk metric compares total liabilities to the combined value of equity and debt, allowing investors to assess the extent of asset dependence on creditors and determine the business's margin of safety when scaling green technologies.

Competitors of Seer, Inc.